Alphamab Oncology (9966.HK)
| Previous close | 4.210 |
| Open | 4.270 |
| Bid | 4.180 x N/A |
| Ask | 4.210 x N/A |
| Day's range | 4.140 - 4.460 |
| 52-week range | 2.000 - 13.460 |
| Volume | |
| Avg. volume | 3,840,476 |
| Market cap | 4.025B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.250 |
| Earnings date | 15 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.06 |
PR NewswireAlphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China
Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of Alphamab Oncology ("the Company"), entered into a licensing agreement (the "Licensing Agreement") on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK).
Simply Wall St.High Growth Tech Stocks To Watch In Hong Kong This September 2024
As global markets show signs of recovery with technology stocks leading the charge, Hong Kong's tech sector remains a focal point for investors seeking high growth opportunities. Amidst this dynamic landscape, identifying promising tech stocks involves evaluating their innovation potential, market position, and resilience to economic fluctuations.
PR NewswireAlphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European Society for Medical Oncology Congress (ESMO Congress 2024) from September 13 to 17, 2024, in Barcelona, Spain. Both were pooled analysis of two phase I clinical studies of JSKN003 conducted in Australia and China on platinum-resistant ovarian cancer and advanced HER2-positive (IHC 3+) solid tumors.
